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Background: Nifekalant, a ﬁrst-line drug for the treatment of ventricular tachycardia/ventricular
ﬁbrillation (VT/VF) in Japan, has been known to prolong the QT interval; however, the incidence of
excess QT/QTc prolongation and subsequent torsades de pointes (TdP) has not yet been reported.
Methods: The QT/QTc interval and occurrence of TdP during nifekalant therapy were evaluated in 1402
emergency patients with VT/VF.
Results: Thirty-ﬁve cases (2.5%) of QT/QTc prolongation and 54 cases (3.9%) of TdP were reported. High
nifekalant doses and long QTc intervals were associated with frequent TdP. The incidence of TdP was
1.4% for QTc intervals o0.43, 3.9% for those 0.44–0.49, 5.3% for those 0.50–0.55, 7.3% for those 0.56–
0.61, 11.1% for those 0.62–0.67, and 12.5% for those Z0.68. The odds ratio for TdP was elevated in
women (2.48); in patients with any heart disease (4.68), New York Heart Association (NYHA) III or IV
(1.81), Forrester subset 2 or worse (2.13), depressed cardiac function (1.86), or liver dysfunction (2.06);
and in patients who were receiving concomitant drugs (2.67). In 42 patients (77.8%), TdP required
treatment with direct current shock or a second drug.
Conclusion: Nifekalant was effective for refractory VT/VF, although careful observation of the QT/QTc
interval and possible occurrence of TdP is required, especially in high-risk patients.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Nifekalant hydrochloride was ﬁrst approved by the Japanese
Ministry of Health, Labour and Welfare in 1999 and is now used
as a ﬁrst-line antiarrhythmic drug for refractory ventricular
tachyarrhythmias in the country [1]. Nifekalant is a class III
antiarrhythmic agent; thus, it highly selectively blocks the IKr
channel and increases the duration of the action potential in
myocardial cells, which prolongs the effective refractory period
and exerts strong antiarrhythmic effects[2–4]. In recent clinical
studies, nifekalant was reported to be safe [5] and effective for
terminating arrhythmia attacks and preventing the recurrence of
life-threatening refractory ventricular arrhythmia [6–8]. In addi-
tion, it suppressed the induction of ventricular tachycardia (VT)
and ventricular ﬁbrillation (VF) induced by programmed electrical
stimulation [9,10]. Moreover, it improved the rate of return of
spontaneous circulation in patients with shock-resistant in-hos-
pital [11] or out-of-hospital cardiac arrest [12]).rt Rhythm Society. Published by EHowever, it is well known that nifekalant prolongs the QT/QTc
interval on electrocardiograms (ECGs) due to its pharmacological
properties and that it sometimes induces a form of polymorphic
ventricular tachycardia – torsades de pointes (TdP) – due to
excess QT prolongation. In fact, cases of TdP were reported in
the above-mentioned clinical studies.
To determine the safe and effective use of nifekalant in the
clinical setting, it is necessary to investigate the incidence of TdP
during nifekalant therapy. Thus, the purpose of the present study
was to examine the incidence of TdP and its relationship with
QT/QTc prolongation in a large Japanese population. In addition,
we attempted to identify the risk factors associated with TdP
during nifekalant therapy.2. Materials and methods
2.1. Subjects
In this post-marketing clinical survey, we investigated 1402
consecutive patients who received nifekalant at 301 institutionslsevier B.V. All rights reserved.
80
90
T. Katoh et al. / Journal of Arrhythmia 29 (2013) 249–254250in Japan between September 1999 and March 2005. The survey
was conducted by Nihon Schering Co. Ltd. (now Bayer Pharma-
ceutical Co. Ltd., Osaka, Japan).
All patients had a medical condition for which nifekalant was
indicated. Patients were eligible for study inclusion if they met
any of the following criteria: (1) unsuccessful use of another
antiarrhythmic agent before nifekalant to treat acute ventricular
arrhythmia; (2) use of another antiarrhythmic agent that was
effective but resulted in an adverse reaction; (3) use of another
antiarrhythmic agent that was effective and did not result in an
adverse reaction but could not be continued due to hemodynamic
deterioration; or (4) the use of no other antiarrhythmic agent
before nifekalant.
A total of 1399 patients were enrolled in the safety evaluation,
which included QT/QTc interval measurements. Three patients
with duplicate records were excluded.
2.2. ECG monitoring and QT/QTc interval measurement
Surface ECG was continuously monitored throughout the nife-
kalant administration, usually with a bipolar chest lead. TdP was
deﬁned as Z3 consecutive polymorphic wide QRS complexes that
showed the characteristic twist around the isoelectric baseline. The
QT/QTc interval immediately before the TdP onset was measured
in patients who developed a TdP episode. When TdP occurred
repeatedly during the nifekalant therapy, the ﬁrst episode was used
in the assessment. When TdP did not occur during nifekalant
administration, the maximum QT/QTc interval during the study
period was used as the representative value.
The QT interval was measured as the length from the onset of
the Q wave to the end of the T wave. The end of the T wave was
manually determined as the point at which the T wave deﬂection
returned to the baseline level. QTc was calculated using Bazett’s
correction (QTc¼QT/RR1/2).
2.3. Nifekalant protocol
The approved protocol for nifekalant administration was an
initial single bolus injection of 0.3 mg/kg followed by continuous
intravenous infusion of 0.4 mg/kg/h; however, in the clinical
setting, physicians were permitted to adjust this regimen accord-
ing to each patient’s condition [13].
2.4. Statistical analysis
All data are expressed as mean7standard deviation. The
chi-square test was used to compare TdP incidences. P values
o0.05 were considered statistically signiﬁcant. Odds ratios (ORs)
and 95% conﬁdence intervals (CIs) were calculated for several
putative risk factors for TdP.0
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Fig. 1. Relationship between QTc and torsades de pointes (TdP). Ordinate, no.,
abscissa, QTc.3. Results
3.1. Patient backgrounds
Mean age was 65.1714.7 years, and 1048 (74.8%) patients
were male. A total of 1287 (92.0%) patients had underlying heart
disease, including 831 with ischemic heart disease, 227 with
cardiomyopathy, and 229 with other organic heart diseases;
73.7% had depressed left ventricular function, i.e., an ejection
fraction (EF) o40%. A total of 339 patients had liver dysfunction,
while 581 patients had renal dysfunction. A total of 1271 (90.9%)
patients were prescribed more than 1 concomitant drug, including
class I and III antiarrhythmic drugs, b-blockers, catecholamines,human atrial natriuretic peptide (hANP), nicorandil, nitroglycerin,
and loop diuretics.
3.2. Nifekalant administration
Nifekalant was administered as a single bolus injection in 277
(19.8%) patients, as a single bolus injection followed by contin-
uous infusion in 751 (53.7%) patients, and as a continuous
infusion only without a single bolus injection in 369 (26.4%)
patients. The single bolus dose was 0.25–0.35 mg/kg in 766
(74.6%) of 1027 patients. Among the 1122 patients who received
a continuous infusion, the starting dose was 0.15–0.24 mg/kg/h in
292 (26.0%), 0.25–0.34 mg/kg/h in 240 (21.4%), 0.35–0.44 mg/kg/h
in 430 (38.3%), and Z0.45 mg/kg/h in 28 (2.5%) patients.
3.3. Arrhythmia control
The efﬁcacy of antiarrhythmics in suppressing ventricular
arrhythmias and the prophylaxis of arrhythmia recurrence was
evaluated in 620 and 964 patients, respectively. The rate of
effectiveness in suppressing ventricular arrhythmias was 69.2%
when nifekalant was used as a ﬁrst-line therapy and 63.9% in
cases that were refractory to treatment with other drugs. The
prophylaxis of acute arrhythmia recurrence by continuous nife-
kalant infusion was successful in 84.8% of cases in which it was
used as a ﬁrst-line therapy and in 82.1% of cases that were
refractory to treatment with other drugs.
3.4. Occurrence of TdP and QT/QTc prolongation
Fifty-four patients (3.86%) had 1 or more episodes of TdP. In
8 patients, TdP occurred during the single bolus administration of
nifekalant; in the remaining 46 patients, it occurred during
continuous infusion of the drug. Thirty-ﬁve patients (2.50%) had
QT/QTc prolongation that was not associated with TdP. Twenty-
three patients required direct current (DC) shock to terminate
TdP, while 13 patients required additional pharmacological ther-
apy to manage TdP, including magnesium and lidocaine.
3.4.1. Relationship between QTc and TdP
Fig. 1 shows the number of patients with and without QTc-
induced TdP episodes immediately before TdP or maximum QTc
among 669 patients from whom ECG data were collected. As Fig. 1
illustrates, long QTc intervals were associated with a high propor-
tion of patients with TdP episodes. The proportion of patients
with TdP steadily rose as the QTc interval increased (Fig. 2): 1 of
72 (1.4%) for a QTc o0.43, 7 of 181 (3.9%) for a QTc of 0.44–0.49,
Table 1
Incidence of torsades de pointes (TdP) during single bolus injection.
Dose No. TdPþ Incidence of TdP (%)
r0.14 mg/kg 34 0 0.00
0.15–0.24 mg/kg 121 1 0.83
0.25–0.34 mg/kg 766 5 0.65
0.35–0.44 mg/kg 62 0 0.00
Z0.45 mg/kg 37 2 5.41
Total 1020 8 0.78
Table 2
Incidence of torsades de pointes (TdP) during continuous infusion.
Dose No. TdPþ Incidence of TdP (%)
r0.14 mg/kg 131 3 2.29
0.15–0.24 mg/kg 292 9 3.08
0.25–0.34 mg/kg 240 11 4.58
0.35–0.44 mg/kg 430 21 4.88
Z0.45 mg/kg 28 2 7.14
Total 1121 46 4.10
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Fig. 2. Incidence of torsades de pointes. Ordinate, %; abscissa, QTc.
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0.56–0.61, 8 of 72 (11.1%) for a QTc of 0.62–0.67, and 4 of 32
(12.5%) for a QTc Z0.68.3.4.2. Relationship between nifekalant dose and TdP
As shown in Tables 1 and 2, the overall incidence of TdP was
higher during continuous infusion than during single injection. In
addition, high nifekalant doses, whether given as a single bolus
injection or continuous infusion, were associated with high TdP
incidence.3.4.3. Patient characteristics and the incidence of TdP
As shown in Table 3, the incidence of TdP during nifekalant
therapy was high (45%) in women; in patients with cardiomyo-
pathy, NYHA functional class III disease, Forrester subset 2 or
3 disease, or liver dysfunction; and in those using b-blockers,
angiotensin-converting enzyme inhibitors (ACE-Is), loop diuretics,
or magnesium. ORs for the occurrence of TdP are shown in Fig. 3.
Elevated ORs were observed for the female sex (OR, 2.48; 95% CI,
1.43–4.30), any heart disease (4.68; 0.64–34.18), NYHA functional
class III or IV disease (1.81; 0.96–3.42), Forrester subset 2 or
worse disease (2.13; 0.87–5.25), depressed cardiac function (1.86;
0.87–3.97), liver dysfunction (2.06; 1.17–3.60), use of concomi-
tant drugs (2.67; 0.64–11.08), and use of loop diuretics (1.74;
1.01–3.00).3.5. Suppression of TdP
In 42 of 54 patients (77.8%), treatments, including DC shock
and a second IV antiarrhythmic drug, were required to suppress
TdP. DC cardioversion was performed in 23 patients and a second
antiarrhythmic drug, including magnesium and lidocaine, was
effective in 13 patients. In 6 patients, TdP was terminated by
a precordial thump or right ventricular overdrive pacing. In
8 patients, TdP resolved spontaneously and quickly without the
need for additional treatment.
3.6. Other adverse reactions
Mild bradyarrhythmias, including sinus bradycardia, sinoatrial
block, and atrioventricular block, occurred in 20 of 1,121 patients
(1.78%) during nifekalant infusion. The incidence of other adverse
reactions was low, including those for liver dysfunction (0.64%),
renal dysfunction (0.5%), and hypotension (0.07%).4. Discussion
4.1. Patient backgrounds and nifekalant effectiveness
Although the patient characteristics varied (Table 3), most
were critically ill from severe underlying cardiac disease. Nifekalant
was used emergently to control life-threatening ventricular arr-
hythmias under these critical conditions. The conditions of 470%
of patients were refractory to other antiarrhythmic drugs, includ-
ing lidocaine, before nifekalant was used. The underlying heart
diseases included ischemic heart disease, cardiomyopathy, and
other organic heart diseases, and many patients had depressed left
ventricular function as indicated by an EF o40%.
This patient population was comparable to those investigated
in large-scale randomized trials conducted in North America and
Europe, including the participants of the CHF-STAT1 [14], EMIAT
[15], CAMIAT [16], and SCD-HeFT [17] trials. In the present
critically ill population, nifekalant had a high rate of effectiveness
with no severe adverse reactions, except TdP. Nifekalant admin-
istration resulted in a success rate of 460% for suppressing
refractory VT/VF and a success rate of 480% for preventing the
acute recurrence of ventricular arrhythmias. These results are
comparable or superior to those reported for other conventional
antiarrhythmic drugs, including intravenous lidocaine, procaina-
mide, and amiodarone [18].
4.2. Relationship between QTc and TdP
Prolongation of the QT/QTc interval is a major risk factor
for severe ventricular arrhythmias [19,20]. It has long been
known that TdP and sudden cardiac death occur frequently in
patients with congenital long QT syndrome (LQTS), e.g., those
with Romano-Ward syndrome and Jervell and Lange-Nielsen
syndrome, and in patients with secondary LQTS, which is induced
by a number of drugs [21–23]. QT interval prolongation might
result in more frequent TdP; however, the relationship between
the degree of prolongation and the exact incidence of TdP has not
been comprehensively investigated [24,25]. Patients with longer
QT intervals do not always have more TdP episodes than do
patients with shorter QT intervals, perhaps because of differences
in sensitivity to arrhythmogenicity, which depend on the degree
of QT prolongation in each patient. In some cases of congenital
LQTS, TdP may be induced by emotional stress or the sudden
auditory stimulation of an alarm clock [26–28]. Thus, sensitivity
may differ with regard to the pathogenesis of QT prolongation,
including the presence of ion-channel gene mutations.
Table 3
Patient characteristics and the incidence of torsades de pointes (TdP).
Characteristics Category No. TdPþ Incidence of TdP (%) P (w2 test)
Sex Male 1047 30 2.87 o .001
Female 352 24 6.82
Age (years) o15 11 0 0 0.641
15–44 92 3 3.26
45–64 469 22 4.69
Z65 827 29 3.51
Any heart disease  110 1 0.91 0.094
þ 1287 53 4.12
AMI  866 33 3.81 0.892
þ 531 21 3.95
OMI  1005 37 3.68 0.568
þ 392 17 4.34
Angina  1267 50 3.95 0.624
þ 130 4 3.08
Cardiomyopathy  1154 41 3.55 0.187
þ 243 13 5.35
Myocarditis  1353 53 3.92 0.578
þ 44 1 2.27 .
Other cardiac diseases  1157 46 3.98 0.638
þ 240 8 3.33
Cardiac surgery  1132 44 3.89 0.949
þ 263 10 3.8
NYHA functional class I 263 5 1.9 0.092
II 256 9 3.52
III 221 14 6.33
IV 470 19 4.04
Forrester subset I 264 6 2.27 0.379
II 138 7 5.07
III 73 4 5.48
IV 339 15 4.42
LVEF o40% 538 24 4.46 0.857
40–49% 190 7 3.68
Z50% 262 10 3.82
Depressed cardiac function  326 8 2.45 0.106
þ 1031 46 4.46
Any other complication  480 10 2.08 0.012
þ 917 44 4.8
Liver dysfunction  1060 33 3.11 0.01
þ 339 21 6.19
Renal dysfunction  818 27 3.3 0.198
þ 581 27 4.65
Any concomitant drugs  127 2 1.57 0.161
þ 1271 52 4.09
Any antiarrhythmic drugs  494 15 3.04 0.236
þ 904 39 4.31
Lidocaine  369 16 4.34 0.582
þ 1029 38 3.69
b-blocker  1135 40 3.52 0.173
þ 263 14 5.32
Cardiac stimulant  531 17 3.2 0.315
þ 867 37 4.27
Catecholamine  652 24 3.68 0.742
þ 746 30 4.02
Digoxin  1277 48 3.76 0.513
þ 121 6 4.96
PDE-III inhibitor  1255 48 3.82 0.827
þ 143 6 4.2
hANP  1243 47 3.78 0.654
þ 155 7 4.52
Other cardiac stimulant  1364 53 3.89 0.778
þ 34 1 2.94
Vasodilator  725 28 3.86 0.999
þ 673 26 3.86
Nicorandil  1207 49 4.06 0.337
þ 191 5 2.62
ACE-I  1261 46 3.65 0.206
þ 137 8 5.84
ARB  1239 50 4.04 0.349
þ 159 4 2.52
Loop diuretics  856 26 3.04 0.044
þ 542 28 5.17
Spironolactone  1228 47 3.83 0.854
þ 170 7 4.12
Magnesium  1258 44 3.5 0.034
þ 140 10 7.14
AMI; OMI; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; PDE-III, phosphodiesterase-III; hANP, human atrial natriuretic peptide; ACE-I,
angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers.
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Any heart disease
NYHA FC III or IV
Forrester subset ≥ 2
Depressed cardiac function
Liver dysfunction
Any concomitant drugs
Use of loop diuretics
0 1 2 3 4 5
Fig. 3. Odds ratios for torsades de pointes. Diamonds, odds ratios; bars, 95%
conﬁdence intervals.
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that greater prolongation of the QT interval resulted in more
frequent TdP in critically ill patients with severe underlying
cardiac disease. QT/QTc prolongation is clearly the most impor-
tant marker of TdP risk; however, the threshold QT/QTc interval
for TdP may differ substantially among individuals. Our ﬁndings
indicate that a QTc interval of 0.6 might be a critical value for TdP
risk because it was associated with an exponential increase in the
rate of TdP (to Z10%) in the patients of the present study.
4.3. Risk factors for TdP occurrence
The results of the present study show that the incidence of TdP
during nifekalant therapy was 45% in women; in patients with
cardiomyopathy, NYHA functional class III disease, Forrester
subset 2 or 3 disease, or liver dysfunction; and in patients using
b-blockers, ACE-Is, loop diuretics, or magnesium. Because of the
critical condition of the patients and the need for emergent
therapy, we have no data on the QT/QTc interval before nifekalant
administration; thus, we were unable to determine the extent
to which QT/QTc was prolonged relative to the period before
nifekalant administration.
It is well known that the long QT/QTc interval and high
incidence of TdP among women is associated with female sex
hormones [29–31] and that heart failure with depressed cardiac
function resulting from severe heart disease is a clear risk factor
for ventricular arrhythmias [32,33]. The use of b-blockers, ACE-Is,
and loop diuretics may be representative of underlying heart
failure. Magnesium use can be explained as the treatment for TdP.
Several factors were associated with elevated ORs for TdP in
the present study. Female sex, any heart disease, and concomitant
drug use were associated with ORs of Z2.0. Therefore, such
factors should also be considered important risks for TdP during
nifekalant therapy.
4.4. Study limitations
The present study has some limitations. The most important of
which is that the study was planned in a retrospective manner as
a post-hoc analysis of post-marketing surveillance in Japan.
In addition, it lacked positive and negative control groups.
Because it was not a randomized prospective trial, the dosage
and protocol for nifekalant use were determined by attending
physicians according to patient condition. We could not conﬁrm
each TdP waveform and determine whether the episode was a
true TdP or a recurrence of original ventricular tachyarrhythmia
in the real ECG recordings. In addition, the types of the original
ventricular tachyarrhythmia, monomorphic or polymorphic,sustained or non-sustained, were not conﬁrmed. The QT mea-
surement method was decided upon and promulgated before the
study began, and the QT intervals were measured by the respec-
tive attending physicians in the emergency room mainly through
the use of monitor ECGs with bipolar chest leads. Because the QT
interval measurements were not performed by a central labora-
tory, some of the measurements may have been inaccurate. In
addition, control ECGs (i.e., before nifekalant use) could not be
obtained due to the patients’ critical conditions.
A future randomized prospective study with a positive control
group is needed to clarify the threshold level of QT prolongation
for the occurrence of TdP.Potential conﬂicts of interests
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